Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Meeting ID

<< Previous

Bullboard Posts

Next >>

Comment by O12009on Dec 04, 2024 10:55am

177 Views

Post# 36345149

RE:Meeting ID

Theralase® is a clinical-stage pharmaceutical company that is in the process of completing a Phase II registration clinical study for bladder cancer.

You're invited to our quarterly Zoom call on Wednesday, December 4th, at 11:00 AM ET. The session will feature a presentation of financial and operational results for the period ending September 30, 2024, along with an update on our Phase II clinical study.

We encourage questions! To ensure we have ample time to review and address them during the call, please submit your questions in advance to mperraton@theralase.com.

Zoom Meeting Link:https://us02web.zoom.us/j/84816819001
Conference Call (for audio only): 1-647-558-0588 (Canada) / 1-646-558-8656(US) – no need to call in if joining via Zoom.

Theralase® Key Investment Highlights:

Clinical Progress: The emrollment phase of the clinical study is nearing completion, with patient enrollment expected to conclude in 2025.
Promising Results: Preliminary data exceeds International Bladder Cancer Group (IBCG) benchmarks recognized by the FDA for recent commercial approvals.
Growth Potential: Competitors in the clinical-stage bladder cancer treatment space boast market caps up to 60 times larger, indicating substantial upside potential.
Analyst Coverage: Analysts rate Theralase® as a “Buy” with a target price over 300% above the current valuation.